By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danish drug discovery firm Nuevolution today said it will employ its screening technology as part of a consortium to identify and develop small molecule drugs against epigenetic disorders.

Nuevolution, based in Copenhagen, Denmark, joins the consortium that also includes EpiTherapeutics, ExpreS2ion Biotechnologies, and the research group of Kristian Helin at the Biotech Research & Innovation Centre at the University of Copenhagen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.